

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

RESIGNATION OF AUDITOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Sunho Biologics, Inc. (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board hereby announces that Deloitte Touche Tohmatsu (“**Deloitte**”) has tendered its resignation letter (the “**Resignation Letter**”) dated 9 September 2025, pursuant to which Deloitte has resigned as the auditor of the Company (the “**Auditor**”) with immediate effect, as the Company could not reach a consensus with Deloitte on the audit fee in respect of the audit of the consolidated financial statements of the Company and its subsidiaries (the “**Group**”) for the year ending 31 December 2025. The Board and the audit committee of the Company (the “**Audit Committee**”) reviewed the audit proposal provided by Deloitte and the audit proposal provided by other professional accounting firms, and having taken into account their respective industry experience, technical knowledge, resource allocation, track record and proposed fees. In view of the more competitive proposal provided by other professional accounting firms, the Board and the Audit Committee consider that the change of Auditor would enhance the cost-effectiveness of the audit of the Company.

Deloitte confirmed in the Resignation Letter that there are no matters connected with its resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”). The Board and the Audit Committee have also confirmed that, save for the audit fee as disclosed above, there is no other disagreement between Deloitte and the Company, and there are no other matters in respect of the change of the Auditor that need to be brought to the attention of the Shareholders.

As at the date of this announcement, the Board confirmed that Deloitte has not yet commenced any audit work on the consolidated financial statements of the Group for the year ending 31 December 2025. It is therefore expected that the change of Auditor will not have any significant impact on the annual audit of the Group for the year ending 31 December 2025.

The Board is in the process of appointing a new Auditor to fill the casual vacancy following the resignation of Deloitte and to hold office until the conclusion of the next annual general meeting of the Company. The Company will make an announcement when such appointment is made.

The Board would like to express its sincere appreciation to Deloitte for their professional services and support to the Company during its tenure.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, 15 September 2025

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng, Dr. YIN Liusong and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.